Inactive Instrument

Press Releases Arix Bioscience plc

Equities

ARIX

GB00BD045071

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arix Bioscience : Notice of Annual General Meeting 2023	23-04-25	PU
Arix Bioscience : Proxy form for AGM 2023	23-04-25	PU
Arix Bioscience : Annual Report & Accounts to 31 December 2022	23-04-25	PU
Arix Bioscience : Interim Results for the Six Months Ended 30 June 2021	21-08-13	AQ
Arix Bioscience : Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer	21-01-12	PU
Arix Bioscience : Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)	21-01-06	PU
Arix Bioscience : Completion of sale of VelosBio	20-12-21	AQ
Arix Bioscience : Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)	20-12-11	PU
Arix Bioscience : Artios and Merck KGaA announce global strategic collaboration	20-12-04	AQ
Arix Bioscience : Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting	20-11-10	PU
Harpoon Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update	20-11-04	PU
Arix Bioscience : VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors	20-10-19	PU
Arix Bioscience : VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma	20-09-07	PU
Arix Bioscience Plc : - Notice of Results	20-08-13	PR
Arix Bioscience Plc : - LogicBio announces IND clearance for LB-001	20-08-10	PR
Pharmaxis: US$7 Million of US Bronchitol Launch Milestone Payment Brought Forward	20-08-05	PU
Arix Bioscience Plc : - Amplyx announces positive Phase 2 data	20-07-20	PR
Arix Bioscience : Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)	20-07-10	PU
Arix Bioscience Plc : - Atox Bio plans NDA submission for Q3 2020	20-07-10	PR
Arix Bioscience Plc : - VelosBio completes $137 million Series B financing	20-07-08	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arix Bioscience plc

Equities

ARIX

GB00BD045071

Press Releases

Filters